Newsroom

Press Release - Life Sciences, Diagnostics & Applied Markets

• 01 Nov 2021
  Agilent Announces New Ion Mobility LC/Q-TOF and Enhanced Solutions for Biotherapeutics at ASMS 2021
• 28 Oct 2021
  Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Triple-Negative Breast Cancer (TNBC)
• 26 Oct 2021
  Agilent Announced as My Green Lab’s First ‘Transformative Level’ Sponsor and First Sponsor of the My Green Lab Certification Program
• 21 Oct 2021
  Agilent PD-L1 IHC 28-8 pharmDx Receives CE-IVD Mark as a Companion Diagnostic Test in Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
• 13 Oct 2021
  Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer
• 28 Sep 2021
  Agilent Announces Thought Leader Award to Bernhard Lendl at the TU Wien (Vienna)
• 07 Sep 2021
  Agilent Announces Thought Leader Award to David R. Liu at the Broad Institute
• 02 Sep 2021
  Agilent and Visiopharm Expand Collaboration with Worldwide Distribution Agreement
• 23 Aug 2021
  Agilent Companion Diagnostic Expands CE-IVD Mark in Europe to Include Esophageal Cancer
• 19 Aug 2021
  Researchers Develop COVID-19 Severity Screening Method Based on the Agilent Cary 630 FTIR Spectrometer